Addex Therapeutics Ltd. (APE1)

Overview

Addex Therapeutics Ltd is a development-stage biopharmaceutical company based in Geneva, Switzerland, committed to the discovery, development, and commercialization of innovative small-molecule pharmaceutical products aimed at treating central nervous system (CNS) disorders. Founded in 2002 and originally known as Addex Pharmaceuticals Ltd, the company specializes in the exploration of G-protein coupled receptors, a crucial area for neuropharmacology. Addex Therapeutics has established several critical collaborations and license agreements with industry-leading pharmaceutical companies, including Janssen Pharmaceuticals Inc., Indivior PLC, and The Charcot-Marie-Tooth Association, to advance its research and developmental efforts in bringing novel CNS disorder treatments to market.

Products and Services

Primarily focused on treating Parkinson's disease levodopa-induced dyskinesia (PD-LID) and dystonia, Dipraglurant represents Addex Therapeutics' pioneering effort in addressing movement disorders associated with Parkinson's disease treatments. The development of this compound signifies the company's frontline approach to mitigating the neuromuscular side effects encountered by patients undergoing long-term dopaminergic therapy for Parkinson's disease.

ADX71149 is a testament to Addex Therapeutics' innovative approach towards treating epilepsy and undisclosed CNS disorders. This compound, developed in collaboration with Janssen Pharmaceuticals Inc., exemplifies the company's commitment to expanding its CNS disorder portfolio beyond movement disorders, targeting a broader range of neurological conditions with significant unmet medical needs.

GABAB PAM is focused on the treatment of pain, anxiety, and addiction, showcasing Addex Therapeutics' diversity in targeting various CNS disorders. By modulating the GABAB receptor, this program aims to offer new therapeutic alternatives for patients suffering from conditions that are often challenging to manage with current treatment options, marking an important endeavor in the company's mission to improve quality of life for individuals facing CNS-related ailments.